Professor of Medicine & Biochemistry, McMaster University

Executive Director, Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada

Dr. Weitz is a Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz now focuses his clinical work in the area of thrombosis.

He holds an Endowed Chair in Cardiovascular Research at McMaster University, which is funded by the Heart and Stroke Foundation of Ontario. He also holds the Canada Research Chair (Tier 1) in Thrombosis.

Dr. Weitz received the Medal in Medicine from the Royal College of Physicians and Surgeons of Canada in 1991, the Distinguished Scientist Award from the Heart and Stroke Foundation of Ontario in 1999, the Research Achievement Award from the Canadian Cardiovascular Society in 2006, the Jack Hirsh Award for Outstanding Academic Achievement from McMaster University in 2008, the Innovator Award from McMaster University in 2010, and the Special Recognition Award in Thrombosis from the American Heart Association in 2011.

He is a member of the American Federation of Medical Research, the American Society for Clinical Investigation, and the Association of American Physicians, a Fellow of the American Heart Association, American and European Colleges of Cardiology, American College of Chest Physicians, and the Canadian Academy of Health Sciences. Dr. Weitz gave the Davidson Lecture at the University of Edinburgh in 2000, the Nossel Memorial Lecture at Columbia University in New York in 2003, and the Mosesson Lecture at the Blood Research Institute in Milwaukee in 2008. He directs a well-funded research laboratory that focuses on the biochemistry of blood coagulation and fibrinolysis as it applies to venous and arterial thrombosis. A former Vice-President of Research for the Heart and Stroke Foundation, member of the Board of Directors of the Heart and Stroke Foundation of Ontario, Chair of the Scientific Review Committee for the Heart and Stroke Foundation of Canada, member of the Executive Council on Thrombosis of the American Heart Foundation, and Chair of the Council on Vascular Biology for the American Society of Hematology, Dr. Weitz has published over 425 peer-reviewed papers and 55 textbook chapters.


Emerging anticoagulant strategies.

Fredenburgh JC, Gross PL, Weitz JI.

Arterial thrombosis is accelerated in histidine-rich glycoprotein deficient mice.

Vu TT, Zhou J, Leslie BA, Stafford AR, Fredenburgh JC, Ni R, Qiao S, Vaezzadeh N, Jahnen-Dechent W, Monia BP, Gross PL, Weitz JI.

Idarucizumab for Dabigatran Reversal.

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MW, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Strangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI; FXI-ASO TKA Investigators.

Oral apixaban for the treatment of acute venous thromboembolism.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators.

Apixaban for extended treatment of venous thromboembolism.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators.

Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation.

MacQuarrie JL, Stafford AR, Yau JW, Leslie BA, Vu TT, Fredenburgh JC, Weitz JI.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators.

For additional research publications please visit: https://www.researchgate.net/profile/Jeffrey_Weitz